GlassScriptPhysician profile
Robert H Liebross
NPI 1598850653
$1,599.65
in general payments reported to CMS, 2019-2025
17 companies · $345 in 2025
The $345 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $287 · 2021: $526 · 2023: $188 · 2024: $254 · 2025: $345.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $787.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $786.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viewray Technologies INC | $273.75 | 2021 | |
| Varian Medical Systems, INC. | $235.02 | 2019-2021 | |
| Bioprotect Medical, INC. | $229.51 | 2025 | Bioprotect Balloon Implant System |
| Siemens Medical Solutions USA, INC. | $188.34 | 2024-2025 | Varian Treatment, Eclipse Treatment Planning System For External Beam Radiation Therapy, Truebeam |
| Puma Biotechnology, INC. | $142.51 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $117.86 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $109.68 | 2023 | Opdivo |
| Bayer Healthcare Pharmaceuticals INC. | $43.66 | 2019 | |
| Pharmacosmos Therapeutics INC. | $41.12 | 2023-2024 | Monoferric |
| Novartis Pharmaceuticals Corporation | $36.61 | 2024-2025 | |
| Blue Earth Diagnostics | $31.69 | 2024-2025 | Posluma |
| Novocure INC. | $30.54 | 2023 | Optune |
| Tempus Ai, INC | $28.86 | 2025 | Xt Cdx |
| Gt Medical Technologies, INC | $28.57 | 2023 | Gammatile |
| Adc Therapeutics America, INC. | $24.47 | 2025 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $19.84 | 2024 | |
| Genzyme Corporation | $17.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Liebross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.